Research progress on the mechanism and clinical data of IDO inhibitor in reversing the resistance of malignancies to PD-1 antibody by regulating MDSCs
10.3969/j.issn.1000-8179.2017.18.960
- VernacularTitle:IDO抑制剂调控MDSCs逆转PD-1抗体治疗恶性肿瘤耐药研究进展
- Author:
HAN YING
1
;
REN XIUBAO
Author Information
1. 天津医科大学肿瘤医院生物治疗科
- Keywords:
IDO inhibitor;
MDSCs;
PD-1 antibody;
malignancy
- From:
Chinese Journal of Clinical Oncology
2017;44(18):935-938
- CountryChina
- Language:Chinese
-
Abstract:
PD-1 antibody immunotherapy has been used as a first-line treatment against various malignancies,but resistance to this treatment limits its efficacy.For instance,myeloid derived suppressor cells,myeloid derived suppressor cells induce resistance to PD-1 antibody in a tumor microenvironment.A few combination regimens of an IDO inhibitor plus PD-1 antibody are currently subjected to ongoing clinical trials in the US,and preliminary results have shown that this inhibitor can reverse the resistance of malignancies to PD-1 antibody.This study reviewed the research progress on the resistance mechanism of malignancies to PD-1 antibody and revealed that IDO inhibitor regulates MDSCs to reverse the resistance to PD-1 antibody.This study also described the clinical efficacy of this in-hibitor plus PD-1 antibody.
